PROSPECTIVE, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE III STUDY EVALUATING EFFICACY AND SAFETY OF OCTAGAM 10% IN PATIENTS WITH DERMATOMYOSITIS ("PRODERM STUDY")

Registry ID

GAM10-08

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES M B H

Start date

2019-10-18

Last update

2016-11-04

Conditions

• DERMATOMYOSITIS

Related clinical trials

• A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL TO EVALUATE EFFICACY AND SAFETY OF LENABASUM IN DERMATOMYOSITIS

View on source registry